Hjem
Ernst Asbjørn Liens bilde

Ernst Asbjørn Lien

Emeritus
  • E-posternst.lien@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2020). First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study. ESMO Open. 1-5.
  • Vis forfatter(e) (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.
  • Vis forfatter(e) (2017). Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Research.
  • Vis forfatter(e) (2016). A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. Breast Cancer Research and Treatment. 97-108.
  • Vis forfatter(e) (2015). The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells. PLOS ONE. 19 sider.
  • Vis forfatter(e) (2015). Novel inflammatory biomarkers in primary hyperparathyroidism. European Journal of Endocrinology (EJE). 9-17.
  • Vis forfatter(e) (2014). Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale. European Journal of Oncology Nursing. 1-7.
  • Vis forfatter(e) (2014). Estradiol determines the effects of PTH on ERα-dependent transcription in MC3T3-E1 cells. Biochemical and Biophysical Research Communications - BBRC. 360-365.
  • Vis forfatter(e) (2013). cAMP response element-binding protein interacts with and stimulates the proteasomal degradation of the nuclear receptor coactivator GRIP1. Endocrinology. 1513-1527.
  • Vis forfatter(e) (2013). Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 243-248.
  • Vis forfatter(e) (2013). A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research. 11 sider.
  • Vis forfatter(e) (2013). 1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism apa1 influence bone mineral density in primary hyperparathyroidism. PLOS ONE. 8 sider.
  • Vis forfatter(e) (2012). Vitamin B6 status and interferon-γ-mediated immune activation in primary hyperparathyroidism. Journal of Internal Medicine. 583-591.
  • Vis forfatter(e) (2012). Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Research and Treatment. 693-700.
  • Vis forfatter(e) (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 12 sider.
  • Vis forfatter(e) (2011). Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Annals of Oncology. 582-587.
  • Vis forfatter(e) (2011). Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLOS ONE. 10 sider.
  • Vis forfatter(e) (2011). Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease. European Journal of Endocrinology (EJE). 761-769.
  • Vis forfatter(e) (2010). Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. Scandinavian Journal of Clinical and Laboratory Investigation. 281-286.
  • Vis forfatter(e) (2010). Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clinical Cancer Research. 2176-2186.
  • Vis forfatter(e) (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 13 sider.
  • Vis forfatter(e) (2009). Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. Journal of Clinical Oncology. 3749-3756.
  • Vis forfatter(e) (2009). Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia. Clinical Cancer Research. 7053-7060.
  • Vis forfatter(e) (2009). Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • Vis forfatter(e) (2009). Genotype-guided tamoxifen therapy: time to pause for reflection? The Lancet Oncology. 825-833.
  • Vis forfatter(e) (2008). Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of Bone and Mineral Research. 1267-1277.
  • Vis forfatter(e) (2008). Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase. Endocrinology. 4336-4345.
  • Vis forfatter(e) (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 56-61.
  • Vis forfatter(e) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. S144-S144.
  • Vis forfatter(e) (2006). Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 231-234.
  • Vis forfatter(e) (2006). Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • Vis forfatter(e) (2005). Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. Journal of Steroid Biochemistry and Molecular Biology. 489-498.
  • Vis forfatter(e) (2005). Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A. 6-14.
  • Vis forfatter(e) (2005). Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Research. 4487-4492.
  • Vis forfatter(e) (2004). cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. Journal of Biological Chemistry. 49120-49130.
  • Vis forfatter(e) (2004). Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial. Clinical Cancer Research. 2336-2343.
  • Vis forfatter(e) (2004). Phenotypic expression of the methylenetetrahydrofolate reductase 677C->T polymorphism and flavine cofactor availability in thyroid dysfunction. American Journal of Clinical Nutrition. 1050-1057.
  • Vis forfatter(e) (2004). Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation. Arteriosclerosis, Thrombosis and Vascular Biology. 301-307.
  • Vis forfatter(e) (2003). Tamoxifen administration and metabolism in nude mice and nude rats. Journal of Steroid Biochemistry and Molecular Biology. 361-367.
  • Vis forfatter(e) (2003). Homocysteine and its relations to B-vitamins and smoking in graves' disease before and after treatment. Journal of Internal Medicine. 504-512.
  • Vis forfatter(e) (2003). Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healty women. Journal of Thrombosis and Haemostasis. 2149-2152.
  • Vis forfatter(e) (2003). Determination of choline, betaine, and dimethylglycine in plasma by a high-troughput metod based on normal-phase chromatography-tandem mass spectrometry. Clinical Chemistry. 286-294.
  • Vis forfatter(e) (2003). Characterization of receptor-interacting protein RIP140 in the regulation of SF-1 responsive target genes. Molecular and Cellular Endocrinology. 91-103.
  • Vis forfatter(e) (2003). A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. Journal of the National Cancer Institute. 779-790.
  • Vis forfatter(e) (2002). Tyreotoksisk periodisk paralyse - en uvanlig komplikasjon ved hypertyreose. Tidsskrift for Den norske legeforening. 1029-1031.
  • Vis forfatter(e) (2002). Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. European Journal of Endocrinology (EJE). 583-589.
  • Vis forfatter(e) (2001). Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. American Journal of Medical Genetics. 246-254.
  • Vis forfatter(e) (2001). Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment. Clinical Chemistry. 1738-1741.
  • Vis forfatter(e) (2001). Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Research and Treatment. 21-27.
  • Vis forfatter(e) (2001). Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiology, Biomarkers and Prevention. 967-970.
  • Vis forfatter(e) (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Vis forfatter(e) (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Vis forfatter(e) (2000). Plasma total homocysteine levels during short-term iatrogenic hypothyreoidism. Journal of Clinical Endocrinology and Metabolism (JCEM). 1049-1053.
  • Vis forfatter(e) (1999). Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • Vis forfatter(e) (1999). Influence of aromatase inhibitors on plasma total homocysteine levels in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
  • Vis forfatter(e) (1999). Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
  • Vis forfatter(e) (1999). Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction. Journal of Clinical Oncology. 2633-2688.
  • Vis forfatter(e) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Vis forfatter(e) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Vis forfatter(e) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Vis forfatter(e) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Vis forfatter(e) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Vis forfatter(e) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Vis forfatter(e) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Vis forfatter(e) (1997). Treatment of small cell lung cancer (SCLC) with high dose tamoxifen in combination with epirubicin, cyclophosphamide and oncovin. European Journal of Clinical Pharmacology. 102.
  • Vis forfatter(e) (1997). Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Vis forfatter(e) (1997). Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Vis forfatter(e) (1995). Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Vis forfatter(e) (1995). Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Vis forfatter(e) (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Vis forfatter(e) (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Vis forfatter(e) (1995). Pharmacokinetics of tamoxifen in pre- and post-menopausal women with breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 229-231.
  • Vis forfatter(e) (1995). Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Vis forfatter(e) (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Vis forfatter(e) (1995). Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Vis forfatter(e) (1995). Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Vis forfatter(e) (1994). Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
  • Vis forfatter(e) (1994). High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology. 79-83.
  • Vis forfatter(e) (1992). Intermittent high dose tamoxifen as a potential modifier of multi-drug resistance. European Journal of Cancer. 805-810.
  • Vis forfatter(e) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) (1992). Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) (1992). Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) (1992). High dose tamoxifen as an enhancer of etoposide cytotoxicity.Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. British Journal of Cancer. 833-839.
  • Vis forfatter(e) (1991). Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Vis forfatter(e) (1991). Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Vis forfatter(e) (1991). Distribution of tamoxifen and its metabolites in tissues of rat and man during steady state treatment. Cancer Research. 4837-4844.
  • Vis forfatter(e) (1991). Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Research. 4837-4844.
  • Vis forfatter(e) (1991). Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
  • Vis forfatter(e) (1990). Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
Vitenskapelig foredrag
  • Vis forfatter(e) (2005). Distribution of tamoxifen in serum and breast cancer tissue and its effects on sex hormone-binding globulin (SHBG).
  • Vis forfatter(e) (2004). Pharmacokinetics and pharmacodynamics of tamoxifen.
  • Vis forfatter(e) (2002). Steroidogenesis - Role of Steroidogenic factor-1 and interacting nuclear receptor coregulators.
  • Vis forfatter(e) (2001). Smoking, folate, and MTHFR C677T genotype as interactive determinants of adenomatous and hyperplastic polyps of colorectum.
  • Vis forfatter(e) (2001). Homocysteine and thyroid function.
  • Vis forfatter(e) (2000). Correlation between tamoxifen elimination and biomarker recovery in a promary prevention trial.
  • Vis forfatter(e) (1999). Plasma levels of homocysteine are changed during treatment of hyper- and hypothyroidism.
  • Vis forfatter(e) (1997). Phase 1 and pharmacokinetic study of high dose tamoxifen combined with epirubicin, cyclophosphamide and oncovin.
Leserinnlegg
  • Vis forfatter(e) (2013). Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncologica. 861-U216.
  • Vis forfatter(e) (2004). Letter. Journal of the National Cancer Institute. 883-883.
  • Vis forfatter(e) (2001). Total plasma homocysteine in hypo- and hyperthyroidism: Covariations and causality. Journal of Clinical Endocrinology and Metabolism (JCEM). 1846.
Doktorgradsavhandling
  • Vis forfatter(e) (2007). Nuclear Receptor Coregulators- Role of Protein-Protein Interactions and cAMP/PKA Signaling.
  • Vis forfatter(e) (2007). Betaine and its relation to homocysteine status and one-carbon metabolism in humans : analytical method and biochemical studies.
  • Vis forfatter(e) (2004). Pharmacology of low-dose tamoxifen regimens in breast cancer treatment.
  • Vis forfatter(e) (2004). Graves' disease and hypothyroidism with emphasis on treatment, homocysteine and B-vitamins.
  • Vis forfatter(e) (1991). Tamoxifen pharmacokinetics in breast cancer patients. Analytical methods, pharmacokinetics, tissue distribution and drug interactions. (dr.med.).
Dokumentar
  • Vis forfatter(e) (2004). "En hormonell kriminalhistorie".
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2012). Tamoxifen metabolism and biological activity. 22 sider.
  • Vis forfatter(e) (2011). Steroid Receptor Coactivators and Their Expression, Regulation and Functional Role in Endocrine Responsive and Resistant Breast Cancer. 18 sider.
  • Vis forfatter(e) (2011). Steroid Receptor Coactivators and Endocrine Treatment in Breast Cancer. 32 sider.
  • Vis forfatter(e) (1999). Hormoner og hormonantagonister. 15 sider.
  • Vis forfatter(e) (1998). Legemiddelanalyser og rusmiddelanalyser. 8 sider.
  • Vis forfatter(e) (1994). Utprøving av dataprogrammet "Aldus Persuasion" og "Davis Transview Presenter" som hjelpemidler i forberedelse og gjennomføring av undervisning. 10 sider.
  • Vis forfatter(e) (1991). Tamoxifen uptake in brain tissue and brain metastases in man.
Sammendrag/abstract
  • Vis forfatter(e) (2013). Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. Experimental and clinical endocrinology & diabetes. 1 sider.
  • Vis forfatter(e) (2010). Grapefruit and Liquorice Increase Bioavailable Cortisol in Addison's Disease. Endocrine reviews. 1 sider.
  • Vis forfatter(e) (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 60-60.
  • Vis forfatter(e) (2009). Ki-67 Expression after Tamoxifen Given Preoperatively Predicts Disease Free Survival and Overall Survival in Women with Operable ER-Positive Breast Cancer. Cancer Research. 517S-518S.
  • Vis forfatter(e) (2008). Vitamin D-metabolism and PTH levels show a biphasic seasonal pattern but are not correlated to osteocalcin levels in outpatients from western Norway. Calcified Tissue International. S150-S151.
  • Vis forfatter(e) (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Vis forfatter(e) (2007). Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. S15-S15.
  • Vis forfatter(e) (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Vis forfatter(e) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. S236-S237.
Poster
  • Vis forfatter(e) (2018). A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
  • Vis forfatter(e) (2013). Vitamin D levels in patients with primary hyperparathyroidism; a follow-up study after parathyroidectomy.
  • Vis forfatter(e) (2012). Systemic Inflammation in Primary Hyperparathyroidism: Influences on Plasma Vitamin B6 Levels and Interferon-γ Mediated Immune Activation.
  • Vis forfatter(e) (2011). Differential Expression of Inflammatory and Metabolic Genes in Adipose Tissue of Patients with Primary Huperparathyroidism.
  • Vis forfatter(e) (2010). Expression of Steroid Receptor Coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated patients.
  • Vis forfatter(e) (2009). The Role of PKA and CREB in regulation of the Steroid Receptor Coactivator GRIP1/SRC-2.
  • Vis forfatter(e) (2009). Relations between FSH, SHBG and tamoxifen metabolism during steady state tamoxifen treatment.
  • Vis forfatter(e) (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 osteoblasts.
  • Vis forfatter(e) (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 Osteoblasts.
  • Vis forfatter(e) (2009). HER-2/neu and nuclear receptor coactivators are upregulated in breast cancer tumors during estrogen deprivation.
  • Vis forfatter(e) (2008). Changes in mRNA expression levels of steroid receptor coactivators correlate with treatment response to aromatase inhibition in human breast cancer.
  • Vis forfatter(e) (2007). Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients.
  • Vis forfatter(e) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment.
  • Vis forfatter(e) (2006). ROLES OF cAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) IN REGULATION OF GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 (GRIP1).
  • Vis forfatter(e) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Vis forfatter(e) (2005). Relationship between CYP2D6 and SULT1A1 genotype and serum concentration of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Vis forfatter(e) (2005). Effects of low-dose tamoxifen treatment on expression of drug-metabolising enzymes in rat liver in relation to administration route.
  • Vis forfatter(e) (2005). CHARACTERIZATION OF THE MOLECULAR MECHANISMS BY WHICH THE LEVEL OF NUCLEAR HORMONE RECEPTOR COACTIVATOR GRIP1 IS REGULATED.
  • Vis forfatter(e) (2004). Tamoxifen metabolism and induction of hepatic drug-metabolizing enzymes in nude rats.
  • Vis forfatter(e) (2004). Quantification of serum tamoxifen and metabolites by liquid chromatography-tandem mass spectrometry.
  • Vis forfatter(e) (2002). Tamoxifen metabolism in immunocompromised rats and mice.
  • Vis forfatter(e) (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor–1.
  • Vis forfatter(e) (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1.
  • Vis forfatter(e) (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1.
  • Vis forfatter(e) (2001). Plasma levels of homocysteine are changed during treatment of hyper- and hypo-thyroidism.
  • Vis forfatter(e) (2001). A comparative study of tamoxifen metabolism in immunodeficient rats and nude mice.
  • Vis forfatter(e) (2001). A comparative study of tamoxifen metabolism in immunodeficient nude rats and nude mice.
Fagartikkel
  • Vis forfatter(e) (2022). Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. BMJ Open.

Se fullstendig oversikt over publikasjoner i CRIStin.